HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT) (TOMCAT)
Trans-arterial Treatment of Patients With Intra-hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)
Sponsor: Oslo University Hospital
This PHASE2 trial investigates Chemotherapy Effect and Intrahepatic Cholangiocarcinoma and is currently actively recruiting participants. Oslo University Hospital leads this study, which shows 5 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Jan 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE2
First recorded
Feb 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Oslo University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .